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ABSTRACT
Exosomes are nano-sized vesicles of endolysosomal origin, released by 
several cytotypes in physiological and pathological conditions. Tumor derived 
exosomes, interacting with other cells of the tumor microenvironment, modulate 
tumor progression, angiogenic switch, metastasis, and immune escape. Recently, 
extracellular vesicles were proposed as excellent biomarkers for disease monitoring 
and prognosis in cancer patients. Non-small cell lung cancer (NSCLC) has a poor 
5-year survival rate due to the delay in the detection of the disease. The majority of 
patients are diagnosed in an advanced disease stage. Exosomes might be promising 
beneficial tools as biomarker candidates in the scenario of NSCLC, since they contain 
both, proteins and miRNAs. The clinical case reported in this manuscript is a proof 
of concept revealing that NSCLC exosomes and sorted miRNAs might constitute, in 
a near future, novel biomarkers. This review summarizes the role of exosomes in 
NSCLC, focusing on the importance of exosomal microRNAs in lung cancer diagnosis 
and prognosis.
INTRODUCTION
Biomarkers constitute one of the most studied tools 
to understand and diagnose malignancies and to predict 
the outcome of cancer patients. A valuable biomarker 
is required to be objectively measured and evaluated as 
an indicator of physiological or pathological processes 
or pharmacological responses to a specified therapeutic 
strategy [1].
Extracellular vesicles (EVs) have recently raised a 
considerable interest in the field of biomarker discovery. 
A relevant feature of EV-based biomarker analysis is the 
significant reduction in complexity of the sample when 
compared to whole body fluids [2]. 
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Extracellular vesicles (EVs) are released by several 
cytotypes, constitutively and/or after cell activation. 
Recently, extracellular vesicles have been classified 
in different populations, differing in their molecular 
composition and subcellular origin. The two populations of 
vesicles most studied and characterized are microvesicles 
and exosomes. 
The term exosome was coined by Johnstone et al [3] 
in a study to understand the biologic process underlying 
the differentiation of reticulocytes to mature erythrocytes. 
The authors observed that maturing reticulocytes 
contained large citoplasmatic invaginations filled with 
small membrane vesicles of uniform size (40-100 nm). 
These vesicles were released in the extracellular space 
in order to eliminate transferrin receptor. After ten years, 
Raposo et al. showed that Epstein-Barr virus (EBV)-
transformed B-lymphocytes are able to secrete exosomes 
containing molecules that are essential for the adaptive 
immune response, specifically, dimers of the Major 
Histocompatibility Complex class II (MHCII) bound to 
antigenic peptides to be presented to T cells [4]. These 
vesicles contain a tissue-specific signature composed 
of proteins and selectively packaged RNAs. Patients 
with cancer show higher concentrations of exosomes 
in blood and moreover, these exosomes carry tumor-
specific molecules, such as DNA and their specific gene 
mutations [5]. Therefore, exosomes might become true 
predictive and prognostic biomarkers. More specifically 
in lung cancer, exosomes will be able to identify different 
subpopulations of patients according to their molecular 
characteristics that may be treated with selective targeted 
therapy.
NON-SMALL CELL LUNG CANCER
A poorly early detection, associated with limited 
efficacy of the treatments for advanced disease, is 
responsible for the low survival rates in NSCLC patients 
[6].
The development of new diagnostic, prognostic 
and predictive markers could significantly enhance its 
early detection outcome. Results from the Collaborative 
Advanced Stage Tissue Cancer (CASTLE) network are 
particularly awaited. In fact, this study aims to collect 
tumor, plasma and serum samples from stage IV NSCLC 
patients before treatment to test a panel of biomarkers 
in order to predict response (NCT01574300). Early 
detection is particularly crucial for tumors without clinical 
symptoms during the initial stages of their development, 
such as lung cancer. Stage IIIB/IV NSCLC patients have 
a poor prognosis and the majority of them, not presenting 
a drugable molecular alteration, have a median survival 
around 12 months using platinum based chemotherapy 
doublets [7]. The era of molecular targeted therapy in 
lung cancer started in 2004, when activating mutations 
in the epidermal growth factor receptor (EGFR) and their 
correlation with clinical response to EGFR tyrosine kinase 
inhibitors (TKIs) were discovered [8].
The epidermal growth factor receptor (EGFR), also 
named HER1, is the cell-surface receptor for extracellular 
protein ligands that are members of the epidermal growth 
factor family (EGF-family). The EGFR activating 
mutations are able to confirm sensitivity to EGFR-TKIs. 
Several randomized clinical trials have shown, both in 
Caucasian and Asian population, superior overall response 
rates (ORRs) and progression free survival (PFS) for 
patients receiving EGFR-TKIs (Erlotinib, Gefitinib, 
Afatinib), compared to standard chemotherapy in patients 
with NSCLC harboring tumors with EGFR activating 
mutations [9-11]. EGFR mutations in NSCLC are present 
in the range of 13% to 18% of Caucasian patients, and in 
about 40% of Asian patients [9]. 
Unfortunately, the majority of EGFR-mutant 
NSCLC patients that show an initial radiological 
response to EGFR-TKIs, eventually progress and their 
tumors develop different mechanisms of resistance [12]. 
One most frequent known mechanism of resistance to 
EGFR-TKIs is associated with the appearance of a single 
recurrent missense mutation, T790M, within the EGFR 
kinase domain [12]. The presence of this mutation can be 
also detected ex novo [13, 14]. The mutation is found in 
the methionine residue at position 790, causing a steric 
hindrance in the interaction with the inhibitor, preventing 
its binding to the EGFR kinase domain that still preserves 
catalytic activity [15, 16]. Several strategies are ongoing in 
order to overcome these resistance mechanisms, including 
third generation EGFR-TKIs, like AZD9291 [17].
A similar scenario occurs for other NSCLC 
predictive biomarkers. Specifically, the EML4-ALK 
fusion gene is a predictive biomarker for response to 
first generation ALK-TKIs [18], presenting a significant 
clinical benefit when used in first-line treatment compared 
with chemotherapy for EML4-ALK translocated tumors in 
NSCLC patients [19, 20]. 
Not with standing, the recent emergent knowledge 
on the role of different predictive and prognostic 
biomarkers makes the molecular analysis of the tissue 
mandatory. Due to the small size and the remote 
localization of many NSCLC tumors, obtaining tissue 
for further analysis is a tricky task. Currently, several 
efforts are ongoing in order to obtain all this biological 
information through non-invasive means. Circulating 
tumor cells (CTCs), circulating tumor DNA (ctDNA) and 
exosomes, all different components of the commonly used 
concept “liquid biopsies”, are part of this answer [21]. 
Through new sensitive and faster technologies 
for nucleic acids analysis, such as digital droplet PCR 
(ddPCR) coupled with Next Generation Sequencing 
(NGS) technologies, it was possible to detect and sequence 
ctDNA and CTCs genes in order to exploit them as new 
source of biological informations, since both these liquid 
biopsy components mirrors the genetic and epigenetic 
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status of the tumor mass [22-24].
The detection of CTCs in the blood of cancer 
patients has been usually related to metastatic stages [25, 
26]. However, with these new sensitive technologies, it 
has been demonstrated that CTCs could be detected also in 
early stages of several cancer types, such as in lung cancer, 
thus enhancing their role as predictive and prognostic 
biomarkers [27-29]. Recently, CellSearch® system was 
approved from FDA as first tool for CTCs analysis in order 
to have another prognostic biomarker source on metastatic 
breast cancer [30].
Moreover, it has been demonstrated that is feasible 
to characterize proteomic and miRNA profiling of 
exosomes. Interestingly enough, miRNAs present in the 
exosomes, have been correlated with the presence of some 
specific molecular alterations, such as EGFR mutations, 
among others [31]. 
EXOSOMES IN CANCER PATIENTS: 
ORIGIN AND POTENTIAL CLINICAL 
INTEREST
Exosomes are spherical nano-sized vesicles that 
represent a distinct class of membrane vesicles, with a 
density of 1.13-1.19 g/ml and a diameter of 40-100 nm. 
These vesicles contain a high number of molecular cargo 
such as mRNA, miRNAs, proteins and DNA protected by 
a lipid bilayer.
Exosomes have an endocytic origin and are released 
by different cell types in both normal and pathological 
conditions [32]. The exosomal composition mirrors the 
parental cell, but several proteins, such as CD63, CD81, 
CD9, TSG-101, ALIX, and HSP70, are contained in the 
exosomes released by all cytotypes. These proteins are 
considered exosomal markers and they are commonly 
used to identify the presence of vesicles as true exosomes 
[33]. 
Current models suggest that exosomes are formed 
within the endocytic pathway and released from the 
plasma membrane via multivesicular bodies (MVBs). 
MVBs are formed from early endosome maturation, and 
they can fuse with lysosomes or the plasma membrane. 
When MVBs fuse with lysosomes, their content will 
undergo lysosomal degradation. The fusion of MVBs with 
the plasma membrane induces the release of intraluminal 
vesicles (exosomes) into the extracellular space (Figure 1). 
Exosome formation needs the endosomal sorting complex 
required for transport (ESCRT) [33].
Figure 1: Schematic model of exosome origin and release. Exosomes derived from the intraluminal vesicles (ILVs) of multivesicular 
bodies (MVBs), formed through the reversed budding of the membrane of late endosomes. ILVs encapsulate material from cytoplasm 
including RNA (both mRNAs and miRNAs) and proteins. Multivesicular bodies can fuse with lysosomes to degrade their content or fuse 
with the plasma membrane to release the ILVs into the extracellular space.
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Several studies hypothesize a pleiotropic role for 
tumor derived exosomes; they may affect the growth and 
survival of tumor cells, degradation of the extracellular 
matrix, stromal remodeling, angiogenesis and drug 
resistance as well as modulation of the immune system 
[34].
In this field, the exosomes released from macrophage 
and NK cells may regulate the tumor invasiveness and 
its metastatic ability and may have a role in immune 
cytotoxicity, respectively [35]. It has also been described 
that mast cell-derived exosomes contain mRNAs and 
miRNAs with biological activity, immunological proteins 
(such as MHC-II, CD86, CD40, CD40L, FcƐ-RI subunits 
alpha and beta) and could be involved in B-cell activation, 
inflammation process and immunomodulation [36-38]. 
Extracellular vesicles can also carry drugs and represent 
a promising strategy for drug delivery. Interestingly, 
proteins differentially expressed in extracellular vesicles, 
can be used as biomarkers for early detection, diagnosis 
and prognosis of cancer [21]. 
Specially relevant is the role of extracellular vesicles 
in transferring information between cells. That information 
may be crucial for tumor progression and angiogenesis 
according to a recent published research showing the 
involvement of cancer cells-released exosomes in 
that matter [39]. In fact, several studies support that 
exosomes may play a relevant role in remodeling the 
tumor microenvironment and in tumor progression via 
an enhanced angiogenesis and the preparation of the 
metastatic niche (Figure 2). More specifically, melanoma-
derived exosomes have been shown to promote metastasis 
through the preparation of the metastatic niche by the 
activation of bone marrow-derived progenitor cells [40]. 
Exosomes have been shown to be involved in several 
cellular functions and intrinsic mechanisms of cancer 
where they possibly constitute valuable biomarkers [21]. 
Interestingly enough, although exosomes have been 
better characterized in peripheral blood samples, they can 
be isolated as well from most body fluids, including urine, 
amniotic fluid, serum, pleural effusion, saliva, breast-milk, 
cerebrospinal fluid, and nasal secretions [41].
As previously mentioned, the components of 
Figure 2: Role of exosomes in NSCLC. Exosomes have a key role in : 1 horizontal transfer of mRNAs and miRNAs from cancer 
cells to cells of microenvironment; 2 tumor progression, inducing cells motility; 3 angiogenesis; 4: metastatization; 5: immunosuppression; 
6: drug resistance.
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exosomes are varied and include proteins, lipids and 
different subtypes of RNA, which can be consulted in the 
‘Exosome Content Database’ (www.exocarta.org) [42]. 
Recently, doubled-stranded DNA has been also discovered 
in exosomes opening a new perspective in this field [43].
Currently, the Exosome Content Database contains 
about 4,563 proteins, 1,639 mRNAs, 764 miRNAs 
and 194 lipids. Among the most frequently, identified 
proteins in exosomes are membrane transport and fusion 
proteins, heat-shock proteins, GTPases, MVB biogenesis 
proteins, cytoskeletal proteins, metabolic enzymes, signal 
transduction proteins and carriers. Thanks to proteomic 
analysis, more than 4,400 different proteins have been 
detected by the use of mass spectrometry. Certainly, the 
specific protein composition depends on the cell type or 
tissue source [42, 44].
Exosomes are also enriched in lipids that may 
act as important signaling molecules. They include 
cholesterol, diglycerides, sphingolipids, phospholipids, 
glycerophospholipids and phosphatidylserine, which have 
a role in exosomes recognition and internalization [45]. 
Exosomes are also enriched in bioactive lipids, such as 
prostaglandins and leukotrienes [46]. 
In 2007 Valadi et al. discovered exosomal miRNAs 
[47], a year after Taylor et al. reported that eight miRNAs, 
previously demonstrated as diagnostic markers for ovarian 
cancer might be identified in biopsies of ovarian cancer 
as well as contained in serum exosomes isolated from 
the same patients. These exosomal miRNAs were not 
detectable in normal controls, suggesting that they are 
easily attainable and may be potentially used as diagnostic 
markers, a worthy alternative for biopsy profiling [48]. 
miRNAs are short single-stranded, endogenous, non-
coding RNA molecules that are involved in binding 
partial complementary sequences within the 3′-UTR of 
the target mRNAs. Global gene expression profiles have 
revealed numerous miRNAs that were deregulated in 
cancer compared with normal tissues [48]. The miRNAs 
associated with oncogenesis are also termed “oncomirs”. 
Depending on the main target, oncomirs are generally 
Figure 3: Summary of clinical case report. The upper part of the figure shows the computerized tomography evolution. The patient 
achieved a partial response in 2 months, disease has been stable for 8 more months. The lower part shows a short scheme of exosome 
isolation and the morphological and biochemical analysis of the exosomes collected by the plasma of NSCLC patient. The miRNAs 
expression fold-change, relative to the baseline timepoint, is related to healthy control samples.
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classified as tumor suppressive and oncogenic miRNAs 
where, in general, tumor suppressive molecules repress 
protein-coding oncogenes and oncogenic miRNAs that 
repress protein-coding tumor suppressors. The profile 
of miRNAs found in exosomes is rather specific, since 
particular repertories of miRNAs are selectively sorted 
into exosomes, while other miRNAs are usually excluded. 
As a good example of this important role, our group 
recently demonstrated, in vitro and in vivo, a selective 
sorting of the oncomir miR-21 in exosomes released by 
chronic myelogenous leukemia cell lines after curcumin 
treatment [49]. Furthermore, unlike other subtypes of RNA 
[47], exosomal miRNA profile is similar to the miRNA 
profile of parental cancer cells, increasing the interest of 
scientists in the use of exosomal miRNA for diagnosis 
of cancer [50, 51]. Moreover, the regulatory properties 
attributed to tumor-derived exosomes are essential in 
shaping the tumor microenvironment and promoting 
tumor growth and metastasis [52, 53]. 
Clear examples of potential clinical applications 
can be found in melanoma patients, in which released 
exosomes were demonstrated to contain high levels of 
the proteins Caveolin-1 and CD63 [54]. In addition, in 
glioblastoma patients, exosomes have been described as 
an amenable biomarker for the identification of disease-
specific molecules [55]. Que et al. also demonstrated 
that miR-17-5p and miR-21 were highly expressed in 
exosomes isolated from patients with pancreatic cancer 
(PC). On the one hand, serum exosomal miR-17-5p 
was higher in PC patients than in non-PC individuals 
(with ampullary carcinoma, benign pancreatic tumors or 
chronic pancreatitis) and healthy donors. High levels of 
miR-17-5p were correlated with the presence of metastasis 
and advanced PC stage. On the other hand, the serum 
exosomal miR-21 levels in PC were higher than in cohorts 
of healthy donors and in patients with chronic pancreatitis, 
but they were not correlated with PC differentiation or 
tumor stage [56]. 
Serum levels of miR-141 and miR-375 are shown 
to be correlated with tumor progression in prostate cancer 
[57], showing to be valuable markers in the diagnosis 
of this tumor type. Moreover, Tanaka et al. showed that 
exosomal miR-21 expression is upregulated in serum from 
patients with esophageal squamous cell cancer (ESCC) 
versus serum from patients with benign diseases, without 
systemic inflammation. In that case, exosomal miR-21 
was positively correlated with tumor progression and 
aggressiveness, suggesting that this miRNA might be a 
useful target for cancer therapy [58].
Chiba et al. also indicated that exosomes derived 
from three colorectal cancer (CRC) cell lines contained 
both mRNAs miRNAs, and were delivered into HepG2 
and A549 cells. These novel findings indicate that 
exosomes, containing several RNAs, shuttle between 
different cell types, and most probably may regulate gene 
expression into the recipient cells [59].
MOLECULAR COMPONENTS OF 
EXOSOMES IN NSCLC
As previously described, the molecular profile 
in lung cancer, specifically in NSCLC, plays a crucial 
role in prognosis and prediction of the outcome of our 
patients. The idea to identify specific molecular patterns 
in exosomes isolated from NSCLC patients results very 
attractive. Several exosomal components have been 
studied. In this section, we will accurately describe the 
two more relevant ones, proteins and miRNAs. 
PROTEINS
NSCLC exosomes contain several tumor-
associated proteins, EGFR, KRAS, extracellular matrix 
metalloproteinase inducer (EMMPRIN), claudins and 
RAB-family proteins. EGFR is overexpressed in several 
human cancers and its overexpression correlates with poor 
prognosis in a large number of malignancies, including 
NSCLC. Exosomal mediated transfer of oncogenic EGFR 
from human squamous cell carcinoma to tumor-associated 
endothelial cells was shown to activate MAPK and AKT 
cell signaling pathways and to promote endothelial VEGF 
expression [60]. In order to study EGFR-containing 
exosomes in NSCLC, Huang et al [61] compared the 
exosomes content between tumor biopsies from NSCLC 
patients with chronic inflammation lung tissues. Eighty 
percent of the exosomes isolated from those NSCLC 
samples was positive for surface EGFR by immune 
staining compared to 2% of the exosomes in chronic 
inflammatory lung tissue. 
The possibility to determine the presence of EGFR 
mutations in exosomes could represent a real innovation 
in the development of exosomes as clinically useful liquid 
biomarkers, constituting a reliable tool for diagnosis and 
treatment selection. EGFR incorporated in exosomes 
could generate tollerogenic dendritic cells and Treg cells, 
which lead to the suppression of CD8 cells [61]. Exosomes 
carry proteins that may not only predict the outcomes of 
patients, but may actively participate in tumorigenesis via 
immune system deregulation, as well. Therefore, although 
exosomes may also play an important role in immune 
system regulation, its potential activity against cancer, by 
supporting immunotherapy, remains unknown.
Regarding the potential translation of exosomes 
into NSCLC diagnostic characterization, Jakobsen et 
al demonstrated that exosomal proteins are potential 
diagnostic markers in advanced NSCLC. Plasma isolated 
from 109 NSCLC patients with advanced stage (IIIa-IV) 
disease and 110 matched control subjects was analyzed 
with an Extracellular Vesicle Array (EV Array). This array, 
used to phenotype exosomes, contained 37 antibodies 
targeting lung cancer-related proteins and was used to 
capture exosomes. EV Array constitutes a tool to get 
information on exosomal content with very limited sample 
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requirement and which can be optimized and adjusted to 
fit individual sets of samples [62].
Exosomal proteins may well reflect pathological 
processes associated with the disease. Since some of 
those proteins may play a critical role in tumorigenesis 
they might constitute good diagnostic and prognostic 
biomarkers in NSCLC [63]. 
The idea of obtaining proteomic information 
in lung cancer, from other body fluids beyond blood 
samples, led to Li et al [64] to investigate this extent in 
urine samples. In their experiment, urine samples from 
eight chemo-naïve NSCLC patients were compared with 
samples from ten healthy volunteers. Interestingly enough, 
the analysis showed that NSCLC patients were able to 
release exosomes in urine. Moreover, high expression 
of leucine-rich α-2-glycoprotein (LRG1) measured by 
immunohistochemistry in primary tumor, showed a 
positive correlation rate of 65% with LRG1 presence in 
urine samples, suggesting that LRG1 in urinary exosomes 
might be derived from primary tumor tissue. These 
authors concluded that urinary LRG1 may be a candidate 
biomarker for non-invasive diagnosis of NSCLC in 
selected individuals [64].
Other potential clinical use of the study of exosomes 
in lung cancer patients relays on their suspected role in 
the prediction of treatment resistance. For unselected 
lung cancer populations, platinum doublet chemotherapy 
remains the most beneficial treatment for patients with 
advanced NSCLC. A recent preclinical study on exosomes 
and DNA-damaging Platinum (DDP), an agent that may 
cause interstrand and/or intrastrand crosslinks in the 
DNA of tumor cells, showed that when A549 cells are 
exposed to DDP, the expression levels of several miRNAs 
and mRNAs, usually associated with DDP sensitivity, 
drastically change in exosomes, probably mediating the 
DDP resistance of A549 cells. Exosomes released by 
A549 cells during DDP exposure decreased the sensitivity 
of other A549 cells to DDP, which may be mediated by 
miRNAs and mRNAs exchange by exosomes via cell-to-
cell communication [65].
In summary, there are different potential clinical 
applications of exosomal proteins in NSCLC as well 
as in other malignancies as diagnostic and predictive 
biomarkers. 
MICRORNAS
An important number of clinical trials currently use 
miRNAs profiling [66], in fact, miRNA-based therapeutic 
approaches are being developed by several pharmaceutical 
companies. 
Recent findings revealed the important regulatory 
roles of miRNAs in a complex multistep process of 
invasion-metastasis. Overexpression of miR-126 reduced 
NSCLC cell adhesion, migration, and invasion, which may 
be partially due to the regulation of adaptor protein Crk, 
also known as p38 or proto-oncogene c-Crk [67].
The expression of miR-34a in the H1299 NSCLC 
cell line resulted in massive apoptosis and exogenous 
delivery of lipid formulated miR-34a reduced tumor size 
in a mouse model of NSCLC, suggesting its possible 
therapeutic potential [68].
An overexpression of 12 specific miRNAs (Table 1) 
in NSCLC patients tissue compared to normal lung tissue 
was demonstrated by Yanaihara et al [69], indicating a 
potential diagnostic miRNA signature. Among these, 
selected miRNAs, miR-146a, targeting EGFR, is 
differentially expressed in various cancer histologies. 
Preclinical experiments performed by this group, in 
five different NSCLC cell lines, revealed the miR146a-
dependent suppression of cell growth, induction of 
apoptosis, inhibition of cell migration, and suppression 
of EGFR downstream signaling effectors. Surprisingly, 
miR-146a was also able to enhance the inhibition of cell 
proliferation induced by drugs targeting the EGFR. These 
effects were independent of the EGFR mutation status. 
miR-146a was also shown to be generally downregulated 
in lung cancer patients and low levels of this miRNAs 
correlated with the presence of metastasis [69]. 
Recently, Rodriguez et al. conducted a prospective 
analysis of blood and bronchoalveolar lavage (BAL) 
samples from 30 NSCLC patients and 75 patients without 
oncological diseases. They found that exosomes and 
miRNAs levels were higher in both plasma and BAL 
from NSCLC patients. The authors revealed that miR-
Table 1: Selected overexpressed microRNAs discovered 
in NSCLC
miR-17-3p
miR-21
miR-106a
miR-146
miR-155
miR-191
miR-192
miR-203
miR-205
miR-210
miR-212
miR-214
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126 was only determinated in plasma samples [70]. MiR-
126 inhibits the NSCLC cells proliferation via EGF-like 
domain-containing protein 7 (EGFL7) and targets Sdf-1 
cytokine to reduce the recruitment of mesenchymal stem 
cells and inflammatory monocytes to primary tumors, 
inhibiting lung metastasis appearance [71]. In another 
study, five determined miRNAs were selected from a 
panel of 365 miRNAs in the plasma of 28 NSCLC patients 
and 20 healthy controls. A validation of these five selected 
miRNAs (let7f, miR-20b, miR-30e-3p, miR-223and miR-
301) was independently performed by real-time PCR in 
plasma from 78 NSCLC and 48 controls, and correlated 
with pathologic parameters and survival. Levels of let-
7f, miR-20b and miR-30e-3p were decreased in plasma 
vesicles of NSCLC patients. The levels of let-7f and miR-
30e-3p was able to discriminate between two groups of 
patients for stage of disease and therefore their surgical 
options. More interestingly, plasma levels of miR-30e-3p 
and let-7f in NSCLC patients has been also associated 
with poor clinical outcome [72]. 
The miRNA profile in exosomes is similar to the 
primary tumor profile and this feature may be a powerful 
tool in different aspects such as early diagnosis, prognosis 
and prediction of response. 
After having discussed the role of exosomes in 
the biology of tumor progression and their potential to 
translate the preclinical experience into clinical practice, a 
clinical case followed by our group will be described and 
discussed. With this case, we would like to demonstrate 
that isolation and characterization of exosomes in patients 
with NSCLC is feasible in a daily practice.
CLINICAL CASE
We present a case of a 70 years old woman with 
no relevant past medical history diagnosed with stage 
IV NSCLC, (adenocarcinoma histotype) and harboring 
an EGFR activating mutation by a deletion in exon 19 
(c.2236_2250del15, p.Glu74_Ala750del). The patient was 
treated with Gefitinib 250 mg/daily. After two months of 
treatment, a computerized tomography (CT) scan showed 
a partial response in the primary tumor. The patient 
continued on treatment for a total of 10 months with 
stabilization of disease and an improvement in quality of 
life. 
Before the start the treatment with Gefitinib, a 
blood sample was collected and plasma was separated. 
The plasma sample was processed with a commercial kit 
(Invitrogen™, Carlsbad) to collect exosomes. In order to 
characterize the exosomes, we performed a morphological 
and biochemical analysis. We confirmed exosomes 
characterization by performing Transmission Electron 
Microscopy (TEM) analysis, in order to show that the 
purified vesicles of our patient sample had an average size 
in the range of the exosomal diameter, between 40-100nm, 
what is in agreement with data from literature [39].
Vesicles were also analysed by Western blotting 
using specific antibodies for Alix and TSG-101, both well-
known exosomal markers. These data confirmed that the 
vesicles that were purified from plasma of our patient were 
indeed exosomes (Figure 3). 
Based on literature, we selected eight miRNAs, with 
a documented role in NSCLC [31]. This panel of miRNAs 
was analyzed by TaqMan® Real-time PCR [58]. Relative 
changes in miRNA expression between healthy control 
and patient samples were determined with the ΔΔCt 
method; miR-1228-3p was selected as stable endogenous 
control.
As shown in figure 3, high levels of miR30b, -30c, 
-103, -195, -221, -222 were encapsulated in exosomes. 
These results are concordant with the findings of Garofalo 
et al, indicating that miR-103,-203,-30b-c and -221 -222 
have a prognostic value, as a marker, in lung cancer [31]. 
Yanaihara et al [69] also indicated that the expression of 
12 selected miRNAs in exosomes from NSCLC patients 
could play a role in diagnosis, since they were expressed 
only in exosomes released by NSCLC cells. We found 
a downregulation of miR-122 and miR-203, possibly 
predictive of more aggressive and metastatic tumors [31]. 
Circulating miR-122 was expressed at lower levels in 
patients with EGFR mutated NSCLC compared with wild 
type EGFR NSCLC patients [73]. In concordance with 
these results, our analysis confirmed a downregulation of 
this miRNA in exosomes of our EGFR mutant NSCLC 
patient.
With this single case, we show that this exosomal 
miRNAs profile of our patient is in concordance with 
the data in the literature. We believe that exosomal 
miRNAs may have an important role in future diagnostic 
and prognostic analysis. Our group is currently working 
in this context, to demonstrate the role of exosomes in 
monitoring NCSLC patients during the treatment. These 
observations suggest that NSCLC exosomes and sorted 
miRNAs may have an important role in diagnosis and 
prognosis in a near future. An interesting open question 
regarding the exosomal application in clinical practice it 
could be the standardization of the correlation between 
exosomal features and clinical outcomes. In this context, 
the idea to exploite the correlation between protein and/or 
miRNA levels of exosome (as part of liquid biopsies) and 
tumor tissue, it could be extremely attractive. 
DISCUSSION
Throughout this manuscript, we have described the 
role of exosomes in cancer, principally in lung cancer. 
Exosomes are small vesicles released by cancer cells to the 
extracellular medium and are able to shuttle proteins and 
nucleic acids. Exosomes are involved in several processes 
such as angiogenesis, premetastatic niche preparation and 
regulation of tumor immune system responses.
Exosomes carry several validated and surrogate 
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non-invasive biomarkers with diagnostic, prognostic and 
predictive value. Clinical studies have already described 
exosomes-associated cancer biomarkers for several cancer 
types such as prostate, breast and ovarian cancer as well as 
glioblastoma and melanoma.
The isolation of exosomes and its use in the clinic 
may substitute invasive procedures for diagnosis or for the 
follow-up of cancer patients, mainly in NSCLC, where the 
availability of primary tumor tissue is difficult in most of 
the patients. The development of novel biomarkers and 
the establishment of a fluid-based early detection system 
for lung cancer is crucial to improve the clinical outcome.
This approach brings also positive effects like a 
reduction of complications derived from tumor biopsies, 
the possibility to anticipate progression and even the 
reduction of healthy costs with ambulatory non-invasive 
techniques. Since the markers must be stable, all these 
features make exosomes good candidates for become 
biomarkers in NSCLC. In addition, exosomal proteins and 
miRNAs are protected from RNase/proteinase-dependent 
degradation and thus can be stably detected in circulating 
plasma and serum, making them ideal biomarkers for a 
number of clinical applications [74]. Another reason 
to select exosomes as preferable liquid biopsy tool is 
correlated to their higher concentration in blood of cancer 
patients [75] in comparison with CTCs, that could lead 
exosomes to be more exploitable for isolation and analysis 
methods.
For instance, some biomarkers such as PCA3 
and TMPRSS2 are mRNAs not easily detected in body 
fluids, but are found in exosomes in prostate cancer [76]. 
Compared with traditional biomarkers, exosomes have 
other advantages potentially, these vesicles can travel 
across the endothelium into the circulation allowing 
serum detection. In contrast to invasive biopsy, exosomes 
are effective biomarkers in the diversified diagnosis of 
personalized medicine [77]. 
For these reasons, our group is focusing on the 
potential predictive and prognostic value of exosomes 
collected from NSCLC samples. 
The isolation of exosomes from plasma of patients 
requires specific expertise, because the amount of samples 
is often insufficient to perform the purification with 
ultracentrifugation. Recently, the increasing number of 
commercial kits developed allows researchers to choose 
the most suitable one for different analysis. In our clinical 
case, the purification of exosomes with a commercial kit 
in combination with transmission electron microscopy, 
Western blotting analysis and miRNAs detection allowed 
us to demonstrate the presence of exosomes containing 
miRNAs in plasma of a NSCLC patient and to confirm the 
data of literature regarding the role of exosomal miRNAs.
Exosomes are also attractive in cancer therapy, as 
vehicles for administration of antitumor compounds such 
as anticancer therapies, siRNAs and antigens to target 
recipient cells [78, 79].
Furthermore, in this field, exosomes derived from 
immune cells can be used to develop cancer vaccines. 
Morse et al reported a phase I study of dendritic-derived 
exosomes (dexosomes) immunotherapy in patients with 
advanced NSCLC. Dexosomes were injected in 13 
NSCLC patients for 4 weeks but unfortunately inducing 
only a weak immune response against the tumor [80]. 
Viaud et al developed a new technology to produce highly 
immunogenic dexosomes, currently used in a phase II 
clinical trial to test the clinical benefit of dexosomes to 
maintain immunotherapy in inoperable NSCLC patients 
that responded to chemotherapy [81]. 
These perspectives open infinite possibilities for 
clinical application. Tremendous multidisciplinary efforts 
must be done by basic researchers, oncologists and 
patients, in order to make all this incredible knowledge 
applicable in a real translational oncology scenario.
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